SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Amazon Explores AI Content Marketplace With Media Publishers 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SOLANA BEACH, Calif., Feb. 21, 2018 -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the fourth quarter and full year ended December 31, 2017 on Wednesday, March 7, 2018, after the market closes.
Evoke will hold a conference call on Wednesday, March 7, 2018 at 4:30 pm ET to discuss the results. Participants should dial 1-877-407-0789 (United States) or 1-201-689-8562 (International) and mention Evoke Pharma. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.evokepharma.com.
After the live webcast, the event will be archived on Evoke's website for one year. In addition, a telephonic replay of the call will be available until March 14, 2018. The replay can be accessed by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) with confirmation code 13676791.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through nasal administration. Visit www.EvokePharma.com for more information.
Investor Contact:
The Ruth Group
Tram Bui
Tel: 646-536-7035
[email protected]
